Vascular BioSciences Announces Publication of “A Bioinformatic Algorithm based on Pulmonary Endoarterial Biopsy for Targeted Pulmonary Arterial Hypertension Therapy” in the Current Issue of The Open Respiratory Medicine Journal 

Dec 30, 2023
by admin
Comments are off

Vascular BioSciences Announces Publication of “A Bioinformatic Algorithm based on Pulmonary Endoarterial Biopsy for Targeted Pulmonary Arterial Hypertension Therapy” in the Current Issue of The Open Respiratory Medicine Journal 

Vascular BioSciences Announces Publication of “A Bioinformatic Algorithm based on Pulmonary Endoarterial Biopsy for Targeted Pulmonary Arterial Hypertension Therapy” in the Current Issue of The Open Respiratory Medicine Journal 

Goleta, CA – Vascular BioSciences announces publication of “A Bioinformatic Algorithm based on Pulmonary Endoarterial Biopsy for Targeted Pulmonary Arterial Hypertension Therapy” in the latest issue of The Open Respiratory Medicine Journal (Volume 17, April 10, 2023) by Abraham Rothman, David Mann, Jose A. Nunez, Reinhardt Tarmidi, Humberto Restrepo, Valeri Sarukhanov, Roy Williams and William N. Evans. This article details a bioinformatics approach for ranking currently approved pulmonary arterial hypertension drugs based on gene expression data derived from percutaneously obtained endoarterial biopsies in an animal model of pulmonary hypertension. 

Pulmonary arterial hypertension (PAH) is associated with substantial morbidity and mortality. The existing approved therapeutic agents for PAH primarily focus on three molecular pathways. However, there is a lack of evidence-based methodologies for tailoring therapy to individual patients. The article describes a proposed strategy that employs bioinformatics to assess and rank currently approved pulmonary arterial hypertension drugs. By integrating a minimally invasive biopsy method with gene expression analysis, a systematic ranking system for therapeutic agents was established that can be implemented to better target treatment for patients with pulmonary arterial hypertension.

Dr. Abraham Rothman, M.D. of the Children’s Heart Center, Nevada and Professor of Medicine at the University of Nevada School of Medicine, expressed the significance of their findings. “Obtaining a ranked combination medication regimen through endoarterial biopsies at different stages of the disease presents a potential paradigm shift in determining pulmonary arterial hypertension therapy,” states Dr. Rothman.

Vascular BioSciences CEO and study co-author David Mann emphasized the transformative potential of the research, “This pioneering research not only marks a significant advancement in the understanding of PAH and opens new doors for tailored and more targeted therapeutic interventions,” commented Mann.

A copy of this article can be found here:  https://openrespiratorymedicinejournal.com/VOLUME/17/ELOCATOR/e187430642308160/FULLTEXT/

About Vascular BioSciences

Vascular BioSciences, a diversified biomedical company with operations in California and North Carolina, provides targeted solutions for serious diseases in order to enhance and prolong human life.

Vascular BioSciences makes interventional catheters to obtain endoarterial biopsies, provides molecular diagnostic services, and through its majority owned subsidiary VBS Pharmaceuticals, develops targeted therapeutics for patients with difficult-to-treat diseases.

More information about VBS is available at http://www.vascularbiosciences.com/

For more information, please contact dmann@vascularbiosciences.com